Brookstone Capital Management Iovance Biotherapeutics, Inc. Transaction History
Brookstone Capital Management
- $5.98 Billion
- Q4 2024
A detailed history of Brookstone Capital Management transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Brookstone Capital Management holds 20,583 shares of IOVA stock, worth $123,292. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,583
Previous 20,055
2.63%
Holding current value
$123,292
Previous $188,000
19.15%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding IOVA
# of Institutions
319Shares Held
239MCall Options Held
3.77MPut Options Held
1.7M-
Vanguard Group Inc Valley Forge, PA27.3MShares$164 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY26.6MShares$159 Million6.53% of portfolio
-
Mhr Fund Management LLC New York, NY24MShares$144 Million28.52% of portfolio
-
Black Rock Inc. New York, NY21.2MShares$127 Million0.0% of portfolio
-
State Street Corp Boston, MA13.2MShares$79.1 Million0.01% of portfolio
About IOVANCE BIOTHERAPEUTICS, INC.
- Ticker IOVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 157,800,992
- Market Cap $945M
- Description
- Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...